

Orphan Drugs Market Report by Drug Type (Biological, Non-Biological), Disease Type (Oncology, Hematology, Neurology, Cardiovascular, and Others), Phase (Phase I, Phase II, Phase III, Phase IV), Top Selling Drugs (Revlimid, Rituxan, Copaxone, Opdivo, Keytruda, Imbruvica, Avonex, Sensipar, Soliris, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Stores, and Others), and Region 2024-2032

<https://marketpublishers.com/r/OE93FB3A4600EN.html>

Date: April 2024

Pages: 135

Price: US\$ 3,899.00 (Single User License)

ID: OE93FB3A4600EN

Abstracts

The global orphan drugs market size reached US\$ 214.8 Billion in 2023. Looking forward, IMARC Group expects the market to reach US\$ 541.3 Billion by 2032, exhibiting a growth rate (CAGR) of 10.5% during 2024-2032.

Orphan drugs refer to pharmaceutical products used for the diagnosis, prevention and treatment of rare medical disorders. These drugs are manufactured to meet a specific public health requirement and usually have a limited market as they are produced for a small group of patients. They are effective against numerous oncological, metabolic, hematologic, immunologic, infectious and neurological diseases. Medical ailments, such as lymphoma, leukemia, cystic fibrosis, glioma, pancreatic cancer, ovarian cancer, multiple myeloma and renal cell carcinoma, are often life-threatening, chronic, progressive, degenerative and disabling and require specific treatment alternatives that are effective for their particular symptoms.

Orphan Drugs Market Trends:

The increasing prevalence of cancer and other rare genetic disorders is one of the key

factors driving the growth of the market. Pharmaceutical manufacturers are developing innovative orphan drugs to provide personalized therapy to patients. The market is also being driven by increasing awareness among the masses regarding the benefits of orphan drugs. The emergence of new pharmaceutical drug manufacturers and the implementation of favorable government policies to inhibit the spread of contagious diseases are also contributing to the market growth. Additionally, various product innovations, such as the development of biological orphan drugs, are acting as other growth-inducing factors. These drugs can treat diseases, such as cancer, and reverse the damage caused to the stem cells, which is facilitating their overall demand significantly. Other factors, including improvements in the healthcare infrastructure, along with extensive research and development (R&D) activities, are expected to drive the market further.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global orphan drugs market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on drug type, disease type, phase, top selling drugs and distribution channel.

Breakup by Drug Type:

Biological

Non-Biological

Breakup by Disease Type:

Oncology

Hematology

Neurology

Cardiovascular

Others

Breakup by Phase:

Phase I

Phase II

Phase III

Phase IV

Breakup by Top Selling Drugs:

Revlimid
Rituxan
Copaxone
Opdivo
Keytruda
Imbruvica
Avonex
Sensipar
Soliris
Others

Breakup by Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
Online Stores
Others

Breakup by Region:

North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The report has also analysed the competitive landscape of the market with some of the key players being AbbVie Inc., Alexion Pharmaceuticals Inc., Amgen Inc., Biogen Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG (Roche Holding AG), Jazz Pharmaceuticals Plc, Johnson & Johnson, Merck & Co. Inc., Novartis AG, Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited and Teva Pharmaceutical Industries Ltd.

Key Questions Answered in This Report

1. What was the size of the global orphan drugs market in 2023?
2. What is the expected growth rate of the global orphan drugs market during 2024-2032?
3. What are the key factors driving the global orphan drugs market?
4. What has been the impact of COVID-19 on the global orphan drugs market?
5. What is the breakup of the global orphan drugs market based on the drug type?
6. What is the breakup of the global orphan drugs market based on the disease type?
7. What is the breakup of the global orphan drugs market based on top selling drugs?
8. What is the breakup of the global orphan drugs market based on the distribution channel?
9. What are the key regions in the global orphan drugs market?
10. Who are the key players/companies in the global orphan drugs market?

Contents

1 PREFACE

2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
 - 2.3.1 Primary Sources
 - 2.3.2 Secondary Sources
- 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 INTRODUCTION

- 4.1 Overview
- 4.2 Key Industry Trends

5 GLOBAL ORPHAN DRUGS MARKET

- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast

6 MARKET BREAKUP BY DRUG TYPE

- 6.1 Biological
 - 6.1.1 Market Trends
 - 6.1.2 Market Forecast
- 6.2 Non-Biological
 - 6.2.1 Market Trends
 - 6.2.2 Market Forecast

7 MARKET BREAKUP BY DISEASE TYPE

7.1 Oncology

7.1.1 Market Trends

7.1.2 Market Forecast

7.2 Hematology

7.2.1 Market Trends

7.2.2 Market Forecast

7.3 Neurology

7.3.1 Market Trends

7.3.2 Market Forecast

7.4 Cardiovascular

7.4.1 Market Trends

7.4.2 Market Forecast

7.5 Others

7.5.1 Market Trends

7.5.2 Market Forecast

8 MARKET BREAKUP BY PHASE

8.1 Phase I

8.1.1 Market Trends

8.1.2 Market Forecast

8.2 Phase II

8.2.1 Market Trends

8.2.2 Market Forecast

8.3 Phase III

8.3.1 Market Trends

8.3.2 Market Forecast

8.4 Phase IV

8.4.1 Market Trends

8.4.2 Market Forecast

9 MARKET BREAKUP BY TOP SELLING DRUGS

9.1 Revlimid

9.1.1 Market Trends

9.1.2 Market Forecast

9.2 Rituxan

- 9.2.1 Market Trends
- 9.2.2 Market Forecast
- 9.3 Copaxone
 - 9.3.1 Market Trends
 - 9.3.2 Market Forecast
- 9.4 Opdivo
 - 9.4.1 Market Trends
 - 9.4.2 Market Forecast
- 9.5 Keytruda
 - 9.5.1 Market Trends
 - 9.5.2 Market Forecast
- 9.6 Imbruvica
 - 9.6.1 Market Trends
 - 9.6.2 Market Forecast
- 9.7 Avonex
 - 9.7.1 Market Trends
 - 9.7.2 Market Forecast
- 9.8 Sensipar
 - 9.8.1 Market Trends
 - 9.8.2 Market Forecast
- 9.9 Soliris
 - 9.9.1 Market Trends
 - 9.9.2 Market Forecast
- 9.10 Others
 - 9.10.1 Market Trends
 - 9.10.2 Market Forecast

10 MARKET BREAKUP BY DISTRIBUTION CHANNEL

- 10.1 Hospital Pharmacies
 - 10.1.1 Market Trends
 - 10.1.2 Market Forecast
- 10.2 Retail Pharmacies
 - 10.2.1 Market Trends
 - 10.2.2 Market Forecast
- 10.3 Online Stores
 - 10.3.1 Market Trends
 - 10.3.2 Market Forecast
- 10.4 Others

10.4.1 Market Trends

10.4.2 Market Forecast

11 MARKET BREAKUP BY REGION

11.1 North America

11.1.1 United States

11.1.1.1 Market Trends

11.1.1.2 Market Forecast

11.1.2 Canada

11.1.2.1 Market Trends

11.1.2.2 Market Forecast

11.2 Asia Pacific

11.2.1 China

11.2.1.1 Market Trends

11.2.1.2 Market Forecast

11.2.2 Japan

11.2.2.1 Market Trends

11.2.2.2 Market Forecast

11.2.3 India

11.2.3.1 Market Trends

11.2.3.2 Market Forecast

11.2.4 South Korea

11.2.4.1 Market Trends

11.2.4.2 Market Forecast

11.2.5 Australia

11.2.5.1 Market Trends

11.2.5.2 Market Forecast

11.2.6 Indonesia

11.2.6.1 Market Trends

11.2.6.2 Market Forecast

11.2.7 Others

11.2.7.1 Market Trends

11.2.7.2 Market Forecast

11.3 Europe

11.3.1 Germany

11.3.1.1 Market Trends

11.3.1.2 Market Forecast

11.3.2 France

- 11.3.2.1 Market Trends
- 11.3.2.2 Market Forecast
- 11.3.3 United Kingdom
 - 11.3.3.1 Market Trends
 - 11.3.3.2 Market Forecast
- 11.3.4 Italy
 - 11.3.4.1 Market Trends
 - 11.3.4.2 Market Forecast
- 11.3.5 Spain
 - 11.3.5.1 Market Trends
 - 11.3.5.2 Market Forecast
- 11.3.6 Russia
 - 11.3.6.1 Market Trends
 - 11.3.6.2 Market Forecast
- 11.3.7 Others
 - 11.3.7.1 Market Trends
 - 11.3.7.2 Market Forecast
- 11.4 Latin America
 - 11.4.1 Brazil
 - 11.4.1.1 Market Trends
 - 11.4.1.2 Market Forecast
 - 11.4.2 Mexico
 - 11.4.2.1 Market Trends
 - 11.4.2.2 Market Forecast
 - 11.4.3 Others
 - 11.4.3.1 Market Trends
 - 11.4.3.2 Market Forecast
- 11.5 Middle East and Africa
 - 11.5.1 Market Trends
 - 11.5.2 Market Breakup by Country
 - 11.5.3 Market Forecast

12 SWOT ANALYSIS

- 12.1 Overview
- 12.2 Strengths
- 12.3 Weaknesses
- 12.4 Opportunities
- 12.5 Threats

13 VALUE CHAIN ANALYSIS

14 PORTERS FIVE FORCES ANALYSIS

- 14.1 Overview
- 14.2 Bargaining Power of Buyers
- 14.3 Bargaining Power of Suppliers
- 14.4 Degree of Competition
- 14.5 Threat of New Entrants
- 14.6 Threat of Substitutes

15 PRICE ANALYSIS

16 COMPETITIVE LANDSCAPE

- 16.1 Market Structure
- 16.2 Key Players
- 16.3 Profiles of Key Players
 - 16.3.1 AbbVie Inc.
 - 16.3.1.1 Company Overview
 - 16.3.1.2 Product Portfolio
 - 16.3.1.3 Financials
 - 16.3.1.4 SWOT Analysis
 - 16.3.2 Alexion Pharmaceuticals Inc.
 - 16.3.2.1 Company Overview
 - 16.3.2.2 Product Portfolio
 - 16.3.2.3 Financials
 - 16.3.2.4 SWOT Analysis
 - 16.3.3 Amgen Inc.
 - 16.3.3.1 Company Overview
 - 16.3.3.2 Product Portfolio
 - 16.3.3.3 Financials
 - 16.3.3.4 SWOT Analysis
 - 16.3.4 Biogen Inc.
 - 16.3.4.1 Company Overview
 - 16.3.4.2 Product Portfolio
 - 16.3.4.3 Financials
 - 16.3.4.4 SWOT Analysis

- 16.3.5 Bristol Myers Squibb Company
 - 16.3.5.1 Company Overview
 - 16.3.5.2 Product Portfolio
 - 16.3.5.3 Financials
 - 16.3.5.4 SWOT Analysis
- 16.3.6 F. Hoffmann-La Roche AG (Roche Holding AG)
 - 16.3.6.1 Company Overview
 - 16.3.6.2 Product Portfolio
 - 16.3.6.3 SWOT Analysis
- 16.3.7 Jazz Pharmaceuticals Plc
 - 16.3.7.1 Company Overview
 - 16.3.7.2 Product Portfolio
 - 16.3.7.3 Financials
 - 16.3.7.4 SWOT Analysis
- 16.3.8 Johnson & Johnson
 - 16.3.8.1 Company Overview
 - 16.3.8.2 Product Portfolio
 - 16.3.8.3 Financials
 - 16.3.8.4 SWOT Analysis
- 16.3.9 Merck & Co. Inc.
 - 16.3.9.1 Company Overview
 - 16.3.9.2 Product Portfolio
 - 16.3.9.3 Financials
 - 16.3.9.4 SWOT Analysis
- 16.3.10 Novartis AG
 - 16.3.10.1 Company Overview
 - 16.3.10.2 Product Portfolio
 - 16.3.10.3 Financials
 - 16.3.10.4 SWOT Analysis
- 16.3.11 Pfizer Inc.
 - 16.3.11.1 Company Overview
 - 16.3.11.2 Product Portfolio
 - 16.3.11.3 Financials
 - 16.3.11.4 SWOT Analysis
- 16.3.12 Sanofi S.A.
 - 16.3.12.1 Company Overview
 - 16.3.12.2 Product Portfolio
 - 16.3.12.3 Financials
 - 16.3.12.4 SWOT Analysis

16.3.13 Takeda Pharmaceutical Company Limited

16.3.13.1 Company Overview

16.3.13.2 Product Portfolio

16.3.13.3 Financials

16.3.13.4 SWOT Analysis

16.3.14 Teva Pharmaceutical Industries Ltd

16.3.14.1 Company Overview

16.3.14.2 Product Portfolio

16.3.14.3 Financials

16.3.14.4 SWOT Analysis

List Of Tables

LIST OF TABLES

Table 1: Global: Orphan Drugs Market: Key Industry Highlights, 2023 and 2032

Table 2: Global: Orphan Drugs Market Forecast: Breakup by Drug Type (in Million US\$), 2024-2032

Table 3: Global: Orphan Drugs Market Forecast: Breakup by Disease Type (in Million US\$), 2024-2032

Table 4: Global: Orphan Drugs Market Forecast: Breakup by Phase (in Million US\$), 2024-2032

Table 5: Global: Orphan Drugs Market Forecast: Breakup by Top Selling Drugs (in Million US\$), 2024-2032

Table 6: Global: Orphan Drugs Market Forecast: Breakup by Distribution Channel (in Million US\$), 2024-2032

Table 7: Global: Orphan Drugs Market Forecast: Breakup by Region (in Million US\$), 2024-2032

Table 8: Global: Orphan Drugs Market Structure

Table 9: Global: Orphan Drugs Market: Key Players

List Of Figures

LIST OF FIGURES

Figure 1: Global: Orphan Drugs Market: Major Drivers and Challenges

Figure 2: Global: Orphan Drugs Market: Sales Value (in Billion US\$), 2018-2023

Figure 3: Global: Orphan Drugs Market: Breakup by Drug Type (in %), 2023

Figure 4: Global: Orphan Drugs Market: Breakup by Disease Type (in %), 2023

Figure 5: Global: Orphan Drugs Market: Breakup by Phase (in %), 2023

Figure 6: Global: Orphan Drugs Market: Breakup by Top Selling Drugs (in %), 2023

Figure 7: Global: Orphan Drugs Market: Breakup by Distribution Channel (in %), 2023

Figure 8: Global: Orphan Drugs Market: Breakup by Region (in %), 2023

Figure 9: Global: Orphan Drugs Market Forecast: Sales Value (in Billion US\$),
2024-2032

Figure 10: Global: Orphan Drugs (Biological) Market: Sales Value (in Million US\$), 2018
& 2023

Figure 11: Global: Orphan Drugs (Biological) Market Forecast: Sales Value (in Million
US\$), 2024-2032

Figure 12: Global: Orphan Drugs (Non-Biological) Market: Sales Value (in Million US\$),
2018 & 2023

Figure 13: Global: Orphan Drugs (Non-Biological) Market Forecast: Sales Value (in
Million US\$), 2024-2032

Figure 14: Global: Orphan Drugs (Oncology) Market: Sales Value (in Million US\$), 2018
& 2023

Figure 15: Global: Orphan Drugs (Oncology) Market Forecast: Sales Value (in Million
US\$), 2024-2032

Figure 16: Global: Orphan Drugs (Hematology) Market: Sales Value (in Million US\$),
2018 & 2023

Figure 17: Global: Orphan Drugs (Hematology) Market Forecast: Sales Value (in Million
US\$), 2024-2032

Figure 18: Global: Orphan Drugs (Neurology) Market: Sales Value (in Million US\$),
2018 & 2023

Figure 19: Global: Orphan Drugs (Neurology) Market Forecast: Sales Value (in Million
US\$), 2024-2032

Figure 20: Global: Orphan Drugs (Cardiovascular) Market: Sales Value (in Million US\$),
2018 & 2023

Figure 21: Global: Orphan Drugs (Cardiovascular) Market Forecast: Sales Value (in
Million US\$), 2024-2032

Figure 22: Global: Orphan Drugs (Other Disease Types) Market: Sales Value (in Million

US\$), 2018 & 2023

Figure 23: Global: Orphan Drugs (Other Disease Types) Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 24: Global: Orphan Drugs (Phase I) Market: Sales Value (in Million US\$), 2018 & 2023

Figure 25: Global: Orphan Drugs (Phase I) Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 26: Global: Orphan Drugs (Phase II) Market: Sales Value (in Million US\$), 2018 & 2023

Figure 27: Global: Orphan Drugs (Phase II) Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 28: Global: Orphan Drugs (Phase III) Market: Sales Value (in Million US\$), 2018 & 2023

Figure 29: Global: Orphan Drugs (Phase III) Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 30: Global: Orphan Drugs (Phase IV) Market: Sales Value (in Million US\$), 2018 & 2023

Figure 31: Global: Orphan Drugs (Phase IV) Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 32: Global: Orphan Drugs (Revlimid) Market: Sales Value (in Million US\$), 2018 & 2023

Figure 33: Global: Orphan Drugs (Revlimid) Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 34: Global: Orphan Drugs (Rituxan) Market: Sales Value (in Million US\$), 2018 & 2023

Figure 35: Global: Orphan Drugs (Rituxan) Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 36: Global: Orphan Drugs (Copaxone) Market: Sales Value (in Million US\$), 2018 & 2023

Figure 37: Global: Orphan Drugs (Copaxone) Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 38: Global: Orphan Drugs (Opdivo) Market: Sales Value (in Million US\$), 2018 & 2023

Figure 39: Global: Orphan Drugs (Opdivo) Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 40: Global: Orphan Drugs (Keytruda) Market: Sales Value (in Million US\$), 2018 & 2023

Figure 41: Global: Orphan Drugs (Keytruda) Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 42: Global: Orphan Drugs (Imbruvica) Market: Sales Value (in Million US\$), 2018 & 2023

Figure 43: Global: Orphan Drugs (Imbruvica) Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 44: Global: Orphan Drugs (Avonex) Market: Sales Value (in Million US\$), 2018 & 2023

Figure 45: Global: Orphan Drugs (Avonex) Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 46: Global: Orphan Drugs (Sensipar) Market: Sales Value (in Million US\$), 2018 & 2023

Figure 47: Global: Orphan Drugs (Sensipar) Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 48: Global: Orphan Drugs (Soliris) Market: Sales Value (in Million US\$), 2018 & 2023

Figure 49: Global: Orphan Drugs (Soliris) Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 50: Global: Orphan Drugs (Other Drugs) Market: Sales Value (in Million US\$), 2018 & 2023

Figure 51: Global: Orphan Drugs (Other Drugs) Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 52: Global: Orphan Drugs (Hospital Pharmacies) Market: Sales Value (in Million US\$), 2018 & 2023

Figure 53: Global: Orphan Drugs (Hospital Pharmacies) Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 54: Global: Orphan Drugs (Retail Pharmacies) Market: Sales Value (in Million US\$), 2018 & 2023

Figure 55: Global: Orphan Drugs (Retail Pharmacies) Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 56: Global: Orphan Drugs (Online Stores) Market: Sales Value (in Million US\$), 2018 & 2023

Figure 57: Global: Orphan Drugs (Online Stores) Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 58: Global: Orphan Drugs (Other Distribution Channels) Market: Sales Value (in Million US\$), 2018 & 2023

Figure 59: Global: Orphan Drugs (Other Distribution Channels) Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 60: North America: Orphan Drugs Market: Sales Value (in Million US\$), 2018 & 2023

Figure 61: North America: Orphan Drugs Market Forecast: Sales Value (in Million US\$),

2024-2032

Figure 62: United States: Orphan Drugs Market: Sales Value (in Million US\$), 2018 & 2023

Figure 63: United States: Orphan Drugs Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 64: Canada: Orphan Drugs Market: Sales Value (in Million US\$), 2018 & 2023

Figure 65: Canada: Orphan Drugs Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 66: Asia Pacific: Orphan Drugs Market: Sales Value (in Million US\$), 2018 & 2023

Figure 67: Asia Pacific: Orphan Drugs Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 68: China: Orphan Drugs Market: Sales Value (in Million US\$), 2018 & 2023

Figure 69: China: Orphan Drugs Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 70: Japan: Orphan Drugs Market: Sales Value (in Million US\$), 2018 & 2023

Figure 71: Japan: Orphan Drugs Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 72: India: Orphan Drugs Market: Sales Value (in Million US\$), 2018 & 2023

Figure 73: India: Orphan Drugs Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 74: South Korea: Orphan Drugs Market: Sales Value (in Million US\$), 2018 & 2023

Figure 75: South Korea: Orphan Drugs Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 76: Australia: Orphan Drugs Market: Sales Value (in Million US\$), 2018 & 2023

Figure 77: Australia: Orphan Drugs Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 78: Indonesia: Orphan Drugs Market: Sales Value (in Million US\$), 2018 & 2023

Figure 79: Indonesia: Orphan Drugs Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 80: Others: Orphan Drugs Market: Sales Value (in Million US\$), 2018 & 2023

Figure 81: Others: Orphan Drugs Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 82: Europe: Orphan Drugs Market: Sales Value (in Million US\$), 2018 & 2023

Figure 83: Europe: Orphan Drugs Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 84: Germany: Orphan Drugs Market: Sales Value (in Million US\$), 2018 & 2023

Figure 85: Germany: Orphan Drugs Market Forecast: Sales Value (in Million US\$),

2024-2032

Figure 86: France: Orphan Drugs Market: Sales Value (in Million US\$), 2018 & 2023

Figure 87: France: Orphan Drugs Market Forecast: Sales Value (in Million US\$),
2024-2032

Figure 88: United Kingdom: Orphan Drugs Market: Sales Value (in Million US\$), 2018 &
2023

Figure 89: United Kingdom: Orphan Drugs Market Forecast: Sales Value (in Million
US\$), 2024-2032

Figure 90: Italy: Orphan Drugs Market: Sales Value (in Million US\$), 2018 & 2023

Figure 91: Italy: Orphan Drugs Market Forecast: Sales Value (in Million US\$),
2024-2032

Figure 92: Spain: Orphan Drugs Market: Sales Value (in Million US\$), 2018 & 2023

Figure 93: Spain: Orphan Drugs Market Forecast: Sales Value (in Million US\$),
2024-2032

Figure 94: Russia: Orphan Drugs Market: Sales Value (in Million US\$), 2018 & 2023

Figure 95: Russia: Orphan Drugs Market Forecast: Sales Value (in Million US\$),
2024-2032

Figure 96: Others: Orphan Drugs Market: Sales Value (in Million US\$), 2018 & 2023

Figure 97: Others: Orphan Drugs Market Forecast: Sales Value (in Million US\$),
2024-2032

Figure 98: Latin America: Orphan Drugs Market: Sales Value (in Million US\$), 2018 &
2023

Figure 99: Latin America: Orphan Drugs Market Forecast: Sales Value (in Million US\$),
2024-2032

Figure 100: Brazil: Orphan Drugs Market: Sales Value (in Million US\$), 2018 & 2023

Figure 101: Brazil: Orphan Drugs Market Forecast: Sales Value (in Million US\$),
2024-2032

Figure 102: Mexico: Orphan Drugs Market: Sales Value (in Million US\$), 2018 & 2023

Figure 103: Mexico: Orphan Drugs Market Forecast: Sales Value (in Million US\$),
2024-2032

Figure 104: Others: Orphan Drugs Market: Sales Value (in Million US\$), 2018 & 2023

Figure 105: Others: Orphan Drugs Market Forecast: Sales Value (in Million US\$),
2024-2032

Figure 106: Middle East and Africa: Orphan Drugs Market: Sales Value (in Million US\$),
2018 & 2023

Figure 107: Middle East and Africa: Orphan Drugs Market Forecast: Sales Value (in
Million US\$), 2024-2032

Figure 108: Global: Orphan Drugs Industry: SWOT Analysis

Figure 109: Global: Orphan Drugs Industry: Value Chain Analysis

Figure 110: Global: Orphan Drugs Industry: Porter's Five Forces Analysis

I would like to order

Product name: Orphan Drugs Market Report by Drug Type (Biological, Non-Biological), Disease Type (Oncology, Hematology, Neurology, Cardiovascular, and Others), Phase (Phase I, Phase II, Phase III, Phase IV), Top Selling Drugs (Revlimid, Rituxan, Copaxone, Opdivo, Keytruda, Imbruvica, Avonex, Sensipar, Soliris, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Stores, and Others), and Region 2024-2032

Product link: <https://marketpublishers.com/r/OE93FB3A4600EN.html>

Price: US\$ 3,899.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/OE93FB3A4600EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms

& Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below
and fax the completed form to +44 20 7900 3970